Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 open-label study of Olumiant (baricitinib) in autoinflammatory interferonopathy syndromes (NNS, CANDLE, SAVI, AGS)
2025-000001-16Phase 2
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of baricitinib in Nakajo-Nishimura syndrome (NNS), STING-associated vasculopathy with onset in infancy (SAVI), Aicardi-Goutières syndrome (AGS) and 1 more, sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Mean Daily Diary Scores in Participants With SAVI.
02
Drugs
baricitinib
03
Conditions
Nakajo-Nishimura syndrome (NNS)STING-associated vasculopathy with onset in infancy (SAVI)Aicardi-Goutières syndrome (AGS)Immune disorder
Beyond the preview
Go deeper on 2025-000001-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-000001-16.